Showing posts with label US guided biopsy. Show all posts
Showing posts with label US guided biopsy. Show all posts

Sunday, July 1, 2018

Abbreviated Prostatic MRI

Kuhl et published in Radiology findings of their study in which they explored the accuracy of an abbreviated MRI of the prostate.  Multi-parametric contrast-enhanced MR imaging was performed in men with elevated PSA who after negative transrectal US-guided biopsy underwent state-of-the-art, full multiparametric contrast-enhanced MR imaging at 3.0-T that included high-spatial-resolution structural imaging in several planes, diffusion-weighted imaging at 0, 800, 1000, and 1400 mm2/sec, and dynamic contrast-enhanced MR imaging, obtained without endorectal coil within 34 minutes 19 seconds.

One of four radiologists first reviewed only two sequences of the study
 consisting of single-plane (axial) structural imaging (T2-weighted turbo spin-echo and diffusion-weighted imaging), acquired within 8 minutes 45 seconds (referred to as bi-parametric MR imaging), and established a diagnosis; only thereafter, the remaining full multiparametric contrast-enhanced MR images were read. Men with PI-RADS categories 3–5 underwent MR-guided targeted biopsy. Men with PI-RADS categories 1–2 remained in urologic follow-up for at least 2 years, with rebiopsy (transrectal US-guided or transperineal) when appropriate. 

A total of 542 men, aged 65 years with median PSA of 7 ng/mL, were included. Bi-parametric MR imaging helped detect clinically significant prostate cancer in 138 men. Full multi-parametric contrast-enhanced MR imaging allowed detection of one additional clinically significant prostate cancer (a stage pT2a, intermediate-risk cancer with a Gleason score of 3+4) and caused 11 additional false-positive diagnoses. Diagnostic accuracy for detection of clinically significant cancer of bi-parametric MR imaging was 89.1% (483 of 542) was similar to that of full multi-parametric contrast-enhanced MR imaging 87.2% (473 of 542). 
The authors concluded that bi-parametric MR imaging which can be done with two sequences and without contrast injection in less that 9 minutes allows for detection of clinically significant prostate cancer with a rate equivalent to conventional full multi-parametric contrast-enhanced MR imaging protocols.